Related Experiment Videos
[Hope for gene therapy. Is this the future of tumor treatment?]
Abstract:
Conventional antineoplastic chemotherapy is limited by the low binding specificity of cytostatic agents and the ubiquity of critical target molecules in both neoplastic and normal cells. Recent advances in molecular biology have led to the identification of ever more genetic alterations specific to tumor cells that may serve as targets for gene therapy. Since appropriately designed nucleic acids hybridize to their "target nucleic acid" with extremely high binding specificity, and can be prepared with relative ease, gene therapy is theoretically superior to conventional chemotherapy. However, the low efficacy of currently available gene transfer technologies, the redundancy of genetic control mechanisms, and, for example under antitumor treatment, the multitude of genetic alterations accumulating during tumor progression represent significant problems. With the exception of monogenic disease, therefore, most clinical studies have so far demonstrated the feasibility of gene therapy, rather than its therapeutic efficacy. Ethical considerations rule out germline therapy. In comparison with conventional treatment, the assessment of the risks of this form of therapy should include a consideration of irreversible and reversible damage.
Insights
Gene therapy offers high specificity for cancer treatment, overcoming limitations of conventional chemotherapy. However, challenges in gene transfer efficacy and tumor complexity hinder its widespread therapeutic application.
Area of Science:
- Molecular biology
- Oncology
- Genetics
Context:
- Conventional chemotherapy faces limitations due to low specificity and targeting of normal cells.
- Advances in molecular biology identify tumor-specific genetic alterations for targeted gene therapy.
- Nucleic acid-based therapies offer theoretical advantages in binding specificity over chemotherapy.
Purpose:
- To explore the theoretical superiority of gene therapy over conventional chemotherapy.
- To identify challenges hindering the therapeutic efficacy of gene therapy.
- To compare the risk-benefit profile of gene therapy with conventional treatments.
Summary:
- Gene therapy, utilizing highly specific nucleic acid hybridization, presents a theoretical advantage over conventional chemotherapy by targeting tumor-specific genetic alterations.
- Despite its potential, current gene therapy faces significant hurdles including low gene transfer efficiency, genetic redundancy in tumors, and the complexity of tumor progression.
- While feasible, gene therapy's therapeutic efficacy remains largely unproven, except in monogenic diseases, necessitating careful risk assessment compared to conventional treatments.
Impact:
- Highlights the potential of gene therapy in oncology.
- Identifies key challenges for future gene therapy development.
- Informs risk-benefit analyses for gene therapy implementation.